These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 21828272)

  • 41. Absence of the Shb gene in mixed-lineage leukemia MLL-AF9 cells increases latency in mice despite higher proliferation rates in vitro.
    Jamalpour M; Bergquist E; Welsh M
    Exp Cell Res; 2020 Dec; 397(2):112368. PubMed ID: 33220260
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants.
    Quelen C; Lippert E; Struski S; Demur C; Soler G; Prade N; Delabesse E; Broccardo C; Dastugue N; Mahon FX; Brousset P
    Blood; 2011 May; 117(21):5719-22. PubMed ID: 21474671
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Knockdown of ZFAS1 suppresses the progression of acute myeloid leukemia by regulating microRNA-150/Sp1 and microRNA-150/Myb pathways.
    Gan S; Ma P; Ma J; Wang W; Han H; Chen L; Li X; Wu F; Sun H
    Eur J Pharmacol; 2019 Feb; 844():38-48. PubMed ID: 30502345
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia.
    Prange KHM; Mandoli A; Kuznetsova T; Wang SY; Sotoca AM; Marneth AE; van der Reijden BA; Stunnenberg HG; Martens JHA
    Oncogene; 2017 Jun; 36(23):3346-3356. PubMed ID: 28114278
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells.
    Chen W; Kumar AR; Hudson WA; Li Q; Wu B; Staggs RA; Lund EA; Sam TN; Kersey JH
    Cancer Cell; 2008 May; 13(5):432-40. PubMed ID: 18455126
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Suppression of c-myc and c-myb is tightly linked to terminal differentiation induced by IL6 or LIF and not growth inhibition in myeloid leukemia cells.
    Hoffman-Liebermann B; Liebermann DA
    Oncogene; 1991 Jun; 6(6):903-9. PubMed ID: 1906157
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias.
    Kvinlaug BT; Chan WI; Bullinger L; Ramaswami M; Sears C; Foster D; Lazic SE; Okabe R; Benner A; Lee BH; De Silva I; Valk PJ; Delwel R; Armstrong SA; Döhner H; Gilliland DG; Huntly BJ
    Cancer Res; 2011 Jun; 71(12):4117-29. PubMed ID: 21505102
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?
    Somervaille TC; Cleary ML
    Int J Hematol; 2010 Jun; 91(5):735-41. PubMed ID: 20454944
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer.
    Thorner AR; Parker JS; Hoadley KA; Perou CM
    PLoS One; 2010 Oct; 5(10):e13073. PubMed ID: 20949095
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation.
    Liebermann DA; Hoffman B
    Stem Cells; 1994 Jul; 12(4):352-69. PubMed ID: 7951003
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
    Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
    Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Histone Acetyltransferase Activity of MOF Is Required for
    Valerio DG; Xu H; Chen CW; Hoshii T; Eisold ME; Delaney C; Cusan M; Deshpande AJ; Huang CH; Lujambio A; Zheng YG; Zuber J; Pandita TK; Lowe SW; Armstrong SA
    Cancer Res; 2017 Apr; 77(7):1753-1762. PubMed ID: 28202522
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Deregulated c-Myb expression in murine myeloid leukemias prevents the up-regulation of p15(INK4b) normally associated with differentiation.
    Schmidt M; Koller R; Haviernik P; Bies J; Maciag K; Wolff L
    Oncogene; 2001 Sep; 20(43):6205-14. PubMed ID: 11593429
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction.
    Uttarkar S; Dassé E; Coulibaly A; Steinmann S; Jakobs A; Schomburg C; Trentmann A; Jose J; Schlenke P; Berdel WE; Schmidt TJ; Müller-Tidow C; Frampton J; Klempnauer KH
    Blood; 2016 Mar; 127(9):1173-82. PubMed ID: 26631113
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
    Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
    Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
    Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
    Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C.
    Zhu N; Chen M; Eng R; DeJong J; Sinha AU; Rahnamay NF; Koche R; Al-Shahrour F; Minehart JC; Chen CW; Deshpande AJ; Xu H; Chu SH; Ebert BL; Roeder RG; Armstrong SA
    J Clin Invest; 2016 Mar; 126(3):997-1011. PubMed ID: 26878175
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of complex genomic breakpoint junctions in the t(9;11) MLL-AF9 fusion gene in acute leukemia.
    Super HG; Strissel PL; Sobulo OM; Burian D; Reshmi SC; Roe B; Zeleznik-Le NJ; Diaz MO; Rowley JD
    Genes Chromosomes Cancer; 1997 Oct; 20(2):185-95. PubMed ID: 9331569
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models.
    Minzel W; Venkatachalam A; Fink A; Hung E; Brachya G; Burstain I; Shaham M; Rivlin A; Omer I; Zinger A; Elias S; Winter E; Erdman PE; Sullivan RW; Fung L; Mercurio F; Li D; Vacca J; Kaushansky N; Shlush L; Oren M; Levine R; Pikarsky E; Snir-Alkalay I; Ben-Neriah Y
    Cell; 2018 Sep; 175(1):171-185.e25. PubMed ID: 30146162
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.
    Thiel AT; Feng Z; Pant DK; Chodosh LA; Hua X
    Haematologica; 2013 Jun; 98(6):918-27. PubMed ID: 23349306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.